AR115666A1 - Formas sólidas de 2-(3,5-dicloro-4-((5-isopropil-6-oxo-1,6-dihidropiridazin-3-il)oxi)fenil)-3,5-dioxo-2,3,4,5-tetrahidro-1,2,4-triazin-6-carbonitrilo - Google Patents

Formas sólidas de 2-(3,5-dicloro-4-((5-isopropil-6-oxo-1,6-dihidropiridazin-3-il)oxi)fenil)-3,5-dioxo-2,3,4,5-tetrahidro-1,2,4-triazin-6-carbonitrilo

Info

Publication number
AR115666A1
AR115666A1 ARP190101846A ARP190101846A AR115666A1 AR 115666 A1 AR115666 A1 AR 115666A1 AR P190101846 A ARP190101846 A AR P190101846A AR P190101846 A ARP190101846 A AR P190101846A AR 115666 A1 AR115666 A1 AR 115666A1
Authority
AR
Argentina
Prior art keywords
dihydropyridazin
carbonitrile
dioxo
tetrahydro
dichloro
Prior art date
Application number
ARP190101846A
Other languages
English (en)
Spanish (es)
Original Assignee
Madrigal Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Madrigal Pharmaceuticals Inc filed Critical Madrigal Pharmaceuticals Inc
Publication of AR115666A1 publication Critical patent/AR115666A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP190101846A 2018-07-02 2019-07-01 Formas sólidas de 2-(3,5-dicloro-4-((5-isopropil-6-oxo-1,6-dihidropiridazin-3-il)oxi)fenil)-3,5-dioxo-2,3,4,5-tetrahidro-1,2,4-triazin-6-carbonitrilo AR115666A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862692914P 2018-07-02 2018-07-02

Publications (1)

Publication Number Publication Date
AR115666A1 true AR115666A1 (es) 2021-02-10

Family

ID=67441642

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190101846A AR115666A1 (es) 2018-07-02 2019-07-01 Formas sólidas de 2-(3,5-dicloro-4-((5-isopropil-6-oxo-1,6-dihidropiridazin-3-il)oxi)fenil)-3,5-dioxo-2,3,4,5-tetrahidro-1,2,4-triazin-6-carbonitrilo

Country Status (12)

Country Link
US (3) US20210122740A1 (https=)
EP (2) EP3818057A1 (https=)
JP (2) JP2021530456A (https=)
KR (2) KR102890565B1 (https=)
CN (1) CN112638904A (https=)
AR (1) AR115666A1 (https=)
AU (2) AU2019298236A1 (https=)
CA (1) CA3104860A1 (https=)
IL (2) IL321116A (https=)
MX (3) MX2021000107A (https=)
TW (1) TW202019914A (https=)
WO (1) WO2020010068A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT4406594T (lt) 2012-09-17 2025-12-29 Madrigal Pharmaceuticals, Inc. Skydliaukės hormono analogai
IL266054B2 (en) 2016-10-18 2023-10-01 Madrigal Pharmaceuticals Inc Methods for treating liver disorders or lipid disorders using a THR-BETA agonist
US12338206B2 (en) 2019-02-21 2025-06-24 Nanjing Ruijie Pharma Co., Ltd. Compounds and their uses as thyroid hormone receptor agonists
GEP20247637B (en) 2019-05-08 2024-06-25 Aligos Therapeutics Inc Modulators of thr-b and methods of use thereof
WO2021063367A1 (zh) * 2019-09-30 2021-04-08 苏州科睿思制药有限公司 一种Resmetirom晶型及其制备方法和用途
WO2021129465A1 (zh) * 2019-12-26 2021-07-01 苏州科睿思制药有限公司 一种Resmetirom晶型及其制备方法和用途
US12595254B2 (en) 2020-09-10 2026-04-07 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal form of Resmetirom, preparation method therefor, and use thereof
WO2022086894A1 (en) 2020-10-19 2022-04-28 Teva Pharmaceuticals International Gmbh Solid state forms of resmetirom
KR20230142523A (ko) * 2021-02-01 2023-10-11 마드리갈 파마슈티칼스, 인크. 간 장애 또는 지질 장애의 치료를 위한 로수바스타틴 및 레스메티롬의 치료용 조합
CN114907327A (zh) * 2021-02-10 2022-08-16 杭州领业医药科技有限公司 Resmetirom的晶型及其制备方法和用途
WO2022225827A1 (en) * 2021-04-21 2022-10-27 Merck Sharp & Dohme Llc Novel forms of cyclic dinucleotide compounds
JP2024544538A (ja) * 2021-11-11 2024-12-03 ターンズ・ファーマシューティカルズ・インコーポレイテッド THR-βアゴニストによる肝障害の治療
WO2024263714A1 (en) 2023-06-22 2024-12-26 Madrigal Pharmaceuticals, Inc. BIOMARKERS FOR TREATING LIVER DISORDERS WITH THR-β AGONISTS AND RELATED USES
WO2025011259A1 (zh) * 2023-07-07 2025-01-16 苏州科睿思制药有限公司 瑞司美替罗的晶型及其制备方法和用途
CN119613386A (zh) * 2023-09-14 2025-03-14 杭州科巢生物科技有限公司 一种瑞司美替罗1,4-二氧六环溶剂化合物及其制备方法
WO2025083699A2 (en) 2023-10-16 2025-04-24 Cipla Limited Resmetirom polymorphs and process thereof
US12377104B1 (en) 2024-02-06 2025-08-05 Madrigal Pharmaceuticals, Inc. Methods for treating a fatty liver disease
WO2025171032A1 (en) 2024-02-06 2025-08-14 Madrigal Pharmaceuticals, Inc. Methods for treating a fatty liver disease
WO2025172958A1 (en) * 2024-02-16 2025-08-21 Metrochem Api Pvt Ltd Solid state forms of resmetirom
WO2025231587A1 (zh) * 2024-05-06 2025-11-13 杭州科巢生物科技有限公司 一种瑞司美替罗无水晶型ch及其制备方法
WO2026067708A1 (zh) * 2024-09-30 2026-04-02 齐鲁制药有限公司 瑞司美替罗晶型及其制备方法和用途
WO2026074443A1 (en) 2024-10-01 2026-04-09 Assia Chemical Industries Ltd. Solid state forms of resmetirom

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001051919A2 (en) * 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
PL1919878T3 (pl) * 2005-07-21 2011-03-31 Hoffmann La Roche Pochodne pirydazynonu jako agoniści receptora hormonu tarczycy
LT4406594T (lt) * 2012-09-17 2025-12-29 Madrigal Pharmaceuticals, Inc. Skydliaukės hormono analogai
IL266054B2 (en) * 2016-10-18 2023-10-01 Madrigal Pharmaceuticals Inc Methods for treating liver disorders or lipid disorders using a THR-BETA agonist

Also Published As

Publication number Publication date
US20250074898A1 (en) 2025-03-06
AU2025200189A1 (en) 2025-01-30
IL279700A (en) 2021-03-01
TW202019914A (zh) 2020-06-01
JP2024105460A (ja) 2024-08-06
WO2020010068A1 (en) 2020-01-09
MX2021000107A (es) 2021-05-27
CN112638904A (zh) 2021-04-09
JP2021530456A (ja) 2021-11-11
EP3818057A1 (en) 2021-05-12
EP4552643A3 (en) 2025-07-02
MX2023009701A (es) 2023-08-29
US20250368626A1 (en) 2025-12-04
AU2019298236A1 (en) 2021-01-21
KR102890565B1 (ko) 2025-11-24
IL321116A (en) 2025-07-01
CA3104860A1 (en) 2020-01-09
US20210122740A1 (en) 2021-04-29
KR20250167140A (ko) 2025-11-28
KR20210027454A (ko) 2021-03-10
EP4552643A2 (en) 2025-05-14
MX2024013198A (es) 2024-12-06

Similar Documents

Publication Publication Date Title
AR115666A1 (es) Formas sólidas de 2-(3,5-dicloro-4-((5-isopropil-6-oxo-1,6-dihidropiridazin-3-il)oxi)fenil)-3,5-dioxo-2,3,4,5-tetrahidro-1,2,4-triazin-6-carbonitrilo
CL2019001340A1 (es) Formas cristalinas de un inhibidor de magl.
CL2019000992A1 (es) Conjugados de pirrolobenzodiazepina.
MX2018012287A (es) Metodos de tratamiento para enfermedades colestasicas y fibroticas.
ECSP21081726A (es) Inhibidores de dihidroorotato deshidrogenasa
MX362339B (es) Forma de sal de un inhibidor de histona metiltransferasa humana ezh2.
CL2008002038A1 (es) Compuestos derivados de 3-fenil-1,2-oxazol, inhibidores de canales de sodio; y su uso para el tratamiento de un trastorno de dolor.
AR101994A1 (es) COMPUESTOS DE PIRROLIDINA ANTAGONISTAS DE INTEGRINA avb6
AR107456A1 (es) Inhibidor de pde1
PE20152032A1 (es) Compuestos de 3,4-dihidroisoquinolin-2(1h)-il
CO2022004589A2 (es) Uso de un agonista del receptor de orexina 2 para el tratamiento de la somnolencia excesiva
UY37517A (es) Métodos de síntesis de compuestos tiazoles sustituidos
FR2974189B1 (fr) Systeme d'imagerie comprenant une lentille de fresnel
IL269589B (en) Automatic probe reinsertion
CL2017001164A1 (es) Compuesto de diaril isoxazolina
CL2021000797A1 (es) Una ayuda para la deposición de fluidos agrícolas.
AR104935A1 (es) Formas cristalinas de un inhibidor de histona deacetilasa
EA202192453A1 (ru) Полиморфы и сокристаллы активатора кардиотропонина
DK3609493T3 (da) Furazidin til behandling af en vaginal bakterieinfektion forårsaget af gardnerella vaginalis eller atopobium vaginae
EA202190694A1 (ru) Композиция поверхностно-активных веществ и ее применение
MX2021009423A (es) Formas cristalinas de un inhibidor de la janocinasa 2 (jak2).
TW202615431A (zh) 2-(3,5-二氯-4-((5-異丙基-6-側氧基-1,6-二氫噠嗪-3-基)氧)苯基)-3,5-二側氧基-2,3,4,5-四氫-1,2,4-三嗪-6-腈之固體型式
EA202190695A1 (ru) Композиция поверхностно-активных веществ и ее применение
CL2017001899A1 (es) Sal de tosilato
IL290446A (en) Intraocular lens with extended depth of focus